Genentech Self-Portrait For 2005
Executive Summary
Genentech has set ambitious targets for growth over the next six years - if Roche does not exercise its option to buy out the remainder of the company
<pre> $5 bil. in revenue 5 significant new products 5 new approved products & indications $500 mil. in new revenues via alliances & acquisitions 25% net income as a percentage of revenues </pre> <br /> <br /> |